Who are the top investors in neurotech?
In our neurotechnology market deck, you will find everything you need to understand the market
SUMMARY
Khosla Ventures is the top all-around neurotech investor today, while Dolby Family Ventures is the strongest dedicated specialist.
The ranking changes substantially once neurotech is defined narrowly. We count companies that record from, stimulate or directly interface with the nervous system, which keeps conventional CNS drug portfolios from overwhelming the comparison.
The strongest investors are not simply the funds attached to the biggest rounds. Early entry and repeated follow-on investing matter more because they show who was willing to underwrite a neural technology before human data or commercial credibility made the bet easier.
Khosla stands out because its portfolio spans several architectures rather than one dominant thesis. Synchron, Science Corporation, Kernel, Flow Neuroscience and Bionaut Labs give it exposure to invasive interfaces, non-invasive measurement, stimulation and new ways of physically reaching the brain.
Dolby Family Ventures is the clearest specialist. Paradromics, NeuroBionics, Motif Neurotech, Cala Health, Salvia BioElectronics and NextSense cover cortical recording, endovascular approaches, therapeutic stimulation, peripheral neuromodulation and neural sensing.
BCI investing is becoming easier to separate into genuine long-term conviction and late-stage participation. Founders Fund's repeated Neuralink investments, Prime Movers Lab's early leadership in Paradromics and re.Mind Capital's exposure to Blackrock Neurotech, Precision Neuroscience and Synchron all carry more weight than joining one famous syndicate.
The sector is also moving beyond the assumption that maximum neural bandwidth wins. Beacon Biosignals, NextSense, NeuroBionics, Motif and Salvia point toward a broader market where lower invasiveness, clearer therapeutic endpoints and easier commercialization can matter more than raw interface performance.
Therapeutic neurotech is becoming its own investable category. Dolby, Satori Neuro, Khosla and specialist medtech funds increasingly sit around companies with defined patient populations, regulatory pathways and reimbursement logic rather than open-ended human-computer augmentation.
Large generalists are becoming more relevant, but most still lack specialist depth. GV has the best modality breadth among them, General Catalyst has a credible neural-data record, and Lightspeed is moving up quickly through Neuralink and Science Corporation.
For an early-stage founder, the best investor list is therefore different from the late-stage capital list. Dolby, re.Mind, Satori Neuro and Prime Movers Lab are more useful starting points when the technology is still weird, technical and hard to explain; Khosla, ARCH and larger medtech investors become more important once human data and commercialization dominate the story.
The broader pattern is that neurotech investing is becoming less about backing one iconic brain implant and more about building conviction across several routes into the nervous system. The investors moving up fastest are the ones whose portfolios already reflect that change.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
What actually counts as neurotech when we rank investors?
For this ranking, neurotech covers technologies that record from, stimulate or directly interface with the nervous system, including brain-computer interfaces, neuromodulation, neuroprosthetics and neural sensing.
We leave conventional CNS drug developers out unless the company is built around a technology that directly interacts with neural activity. That keeps the comparison useful. A fund with twenty Alzheimer's drug companies may know neuroscience extremely well, but that does not automatically make it one of the best investors for someone building a brain implant.
The companies that qualify can still look radically different. Neuralink and Paradromics put electrodes into the brain. Precision Neuroscience uses an ultra-thin array placed on the cortical surface. Synchron reaches the brain through blood vessels. Motif Neurotech is developing a tiny stimulator that sits in the skull without touching the brain. Beacon Biosignals builds around EEG. Cala Health stimulates peripheral nerves through a wearable device.
We are therefore ranking investors by repeated neurotech bets, the quality of the companies they backed, how early they entered, whether they kept investing as those companies progressed and how much relevant expertise they appear to bring. One giant Neuralink check alone is not enough to win the ranking.
Why is the neurotech investor ranking changing right now?
The neurotech investor ranking is changing now because large financings are increasingly following human trials, regulatory progress and commercialization plans.
Four of the clearest recent rounds alone add up to about $1.18 billion. Neuralink raised $650 million after expanding its human implant program. Synchron raised $200 million to push its Stentrode platform toward commercialization. Science Corporation raised $230 million while preparing its PRIMA retinal implant for market and expanding other neural-interface programs. Beacon Biosignals extended its Series B to $97 million for its EEG and brain-data platform.
There is also meaningful capital below those headline rounds. Salvia BioElectronics raised $60 million to complete development and prepare the commercial launch of its neuromodulation treatment for chronic migraine. NeuroBionics recently expanded its seed financing to $10 million for an endovascular neuromodulation platform. Motif Neurotech, after raising $18.75 million in its Series A, received FDA approval to begin its first clinical trial in treatment-resistant depression.
The stronger neurotech portfolios are starting to reveal themselves through follow-on behavior. We can see which funds were around when a technology still looked strange, which ones stayed once clinical risk became the main issue and which investors only arrived when a company was already famous.
| Company | Major recent financing | What investors are funding |
|---|---|---|
| Neuralink | $650M | Expansion of human BCI trials and new applications |
| Science Corporation | $230M | PRIMA commercialization and broader neural engineering |
| Synchron | $200M | Commercialization of the Stentrode BCI |
| Beacon Biosignals | $97M | At-home EEG, diagnostics and brain-data infrastructure |
| Salvia BioElectronics | $60M | Clinical development and launch preparation for migraine neuromodulation |
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Is Khosla Ventures the best all-around neurotech investor?
Yes. Khosla Ventures currently has the strongest combination of neurotech breadth, early conviction and enough capital to stay involved once companies become expensive.
Synchron is probably the cleanest example. Khosla invested in the company in 2021, when the idea of delivering a permanent brain-computer interface through a blood vessel still looked like an unusually aggressive medtech bet. Synchron has since implanted its Stentrode in humans, expanded clinical work in the United States and Australia and raised hundreds of millions of dollars.
Khosla also backed Kernel's attempt to make sophisticated brain measurement non-invasive, Flow Neuroscience's brain-stimulation treatment for depression and Bionaut Labs, whose tiny remotely controlled devices are designed to reach difficult areas of the brain. Khosla led Bionaut's original $20 million financing and its subsequent $43.2 million Series B.
Science Corporation adds the most recent piece. Khosla led a financing of more than $100 million in 2025 and returned in Science's latest $230 million round. Science now has roughly $490 million of invested capital and is trying to commercialize PRIMA while developing additional neural-interface technologies.
The mix is what puts Khosla ahead. Synchron, Kernel, Flow, Bionaut and Science represent very different ways of interacting with the nervous system. Khosla has been willing to finance invasive devices, non-invasive measurement, electrical stimulation and technologies built around physical access to the brain.
For a neurotech company that could eventually need hundreds of millions of dollars, that combination is hard to beat.
If you want more recent data on this point, please see our latest neurotechnology market report.
Is Dolby Family Ventures the deepest specialist neurotech investor?
Yes. Dolby Family Ventures has the most convincing specialist neurotech portfolio we found, and its recent activity makes the case stronger.
Dolby explicitly treats neurotech as part of its precision-neuroscience strategy. Its current portfolio includes Paradromics, NeuroBionics, Motif Neurotech, Cala Health, Salvia BioElectronics and Bionaut Labs, alongside neural sensing companies such as NextSense and neuromodulation businesses such as Magnus Medical.
Several of those companies have crossed important thresholds lately. Paradromics completed its first human recording and later received FDA approval to begin a longer-term clinical study. Motif received FDA approval for its first clinical trial of a therapeutic BCI for treatment-resistant depression. NeuroBionics expanded its seed financing. Salvia raised $60 million as it moved deeper into clinical development and launch preparation.
Dolby was already backing some of these companies years before those milestones. It participated in Paradromics' $20 million seed round in 2021 and returned for the $33 million Series A. It also invested in Motif's Series A and stayed invested in Salvia as the company reached a much larger Series B.
The firm's own portfolio now gives a good picture of how broad neurotech has become. Paradromics records from the cortex. NeuroBionics wants to reach neural targets through the vasculature. Motif stimulates circuits linked to depression. Cala treats tremor through peripheral nerve stimulation. NextSense measures brain activity from the ear.
For an early neurotech founder looking for an investor that already understands why a neural device might take years of engineering, clinical work and regulatory approval, Dolby belongs at or near the top of the call list.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Which specialist neurotech investors stand out after Dolby Family Ventures?
re.Mind Capital, Satori Neuro and Prime Movers Lab form the strongest next group, although they have built very different neurotech portfolios.
re.Mind has one of the most concentrated BCI records. It led Blackrock Neurotech's first institutional $10 million financing, later invested in Precision Neuroscience and currently presents Synchron among its portfolio companies. Its focus on neurological and mental health makes neurotechnology part of the fund's core thesis rather than an occasional deep-tech allocation.
Satori Neuro leans further into the overlap between neurotechnology, brain health and mental health. Amy Kruse, who runs the strategy, previously led human-augmentation investing at Prime Movers Lab and remains on the boards of Paradromics and Cognixion. Satori backed Motif Neurotech and took a board seat, participated in NextSense's $16 million financing and has also invested around continuous mental-health measurement.
Prime Movers Lab has a narrower visible neurotech portfolio today, but its Paradromics bet carries unusual weight. Prime Movers led Paradromics' $20 million seed round and then led the $33 million Series A. It was underwriting high-bandwidth implanted BCI years before Paradromics reached human testing.
We would therefore put re.Mind slightly ahead on breadth within BCI, Satori ahead for the broader brain-health and therapeutic-neurotech intersection, and Prime Movers ahead when the company looks more like frontier engineering than conventional healthcare.
| Investor | Strongest neurotech evidence | Best fit |
|---|---|---|
| re.Mind Capital | Blackrock Neurotech, Precision Neuroscience, Synchron | BCI and neurological technology |
| Satori Neuro | Motif Neurotech, NextSense, neuro-focused portfolio | Therapeutic neurotech, sensing, brain health |
| Prime Movers Lab | Early and repeated leadership in Paradromics | High-risk BCI and frontier neural engineering |
If you want more recent data on this point, please see our latest neurotechnology market report.
Does Founders Fund deserve to rank near the top because of Neuralink?
Founders Fund belongs near the top of the BCI investor list because its Neuralink conviction has been unusually large and persistent, but its broader neurotech portfolio is much thinner than Khosla's or Dolby's.
Founders Fund participated in Neuralink's $205 million Series C, led the company's $280 million Series D and came back again for the $650 million Series E. That sequence is more informative than appearing once in a late-stage syndicate. Neuralink moved from pre-human development to implanted patients during that period, and Founders Fund kept increasing its exposure.
Neuralink itself has also progressed far enough that the investment no longer looks like a pure moonshot. The company said at the beginning of 2026 that 21 participants had received Neuralink implants, up sharply from the five participants it reported when announcing its previous major financing.
Still, Founders Fund does not currently show the same range of neural sensing, neuromodulation, minimally invasive interfaces and therapeutic devices that we see at Dolby or Khosla.
So we would rank Founders Fund very highly for founders building an extremely ambitious BCI company. We would rank several specialists ahead of it for neurotech as a whole.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Who are the strongest investors in brain-computer interfaces specifically?
For brain-computer interfaces, Khosla Ventures, re.Mind Capital, Founders Fund, Dolby Family Ventures and Prime Movers Lab have the clearest combination of conviction and relevant company exposure.
Khosla gets breadth through Synchron and Science. The two companies are pursuing very different paths: Synchron uses an endovascular implant, while Science is building several neural-interface technologies and preparing its retinal system for commercialization.
re.Mind offers a different portfolio. Blackrock Neurotech represents one of the industry's oldest implant platforms. Precision Neuroscience uses a surface array designed to avoid penetrating brain tissue. Synchron adds an endovascular approach. That gives re.Mind exposure to several competing answers to the invasiveness problem.
Prime Movers has concentrated heavily on Paradromics, while Founders Fund has concentrated heavily on Neuralink. In both cases, the concentration comes with years of follow-on commitment rather than a recent one-off investment.
Dolby sits somewhere between those models because it has Paradromics, NeuroBionics and Motif across recording, endovascular neuromodulation and therapeutic stimulation.
Synchron's financing history also shows why we should distinguish between long-term neurotech investors and whoever leads the latest round. ARCH Venture Partners led Synchron's $75 million Series C when the company was moving deeper into clinical development. Double Point Ventures later led the $200 million Series D, with ARCH, Khosla, Bezos Expeditions, NTI and others returning as existing investors.
The latest lead investor is useful information, but repeated exposure across technical and clinical stages tells us much more about who actually understands the sector.
If you want more recent data on this point, please see our latest neurotechnology market report.
Who is strongest in therapeutic neurotech and neuromodulation?
Dolby Family Ventures currently has the strongest therapeutic-neurotech portfolio, with Satori Neuro, Khosla Ventures and several specialist medtech investors close behind in specific niches.
Motif Neurotech is a good example of how this group comes together. Arboretum Ventures led its $18.75 million Series A, while Satori Neuro, Dolby, re.Mind and KdT Ventures participated. Motif is now cleared to begin an early feasibility study of its small, wirelessly powered implant for treatment-resistant depression. Satori's Amy Kruse and Arboretum's Tom Shehab both joined the board.
Salvia BioElectronics gives Dolby another late-stage neuromodulation position. Innovation Industries led Salvia's $60 million Series B, while existing investors including Dolby, INKEF, Panakès, SHS Capital and Thuja Capital returned. The money is being used to finish clinical development and prepare for commercialization of a minimally invasive migraine treatment.
Dolby's Cala Health investment reaches the same theme without an implanted brain device. Cala uses peripheral nerve stimulation to treat action tremor and already has an FDA-cleared commercial product.
Khosla approaches therapeutic neurotech from another direction through Flow Neuroscience, whose electrical brain-stimulation headset is used for depression, and through technologies such as Bionaut that could change how therapies physically reach the brain.
This part of neurotech is easy to miss when attention stays on Neuralink. From an investment perspective, therapeutic stimulation may offer a clearer path to defined patient populations, clinical endpoints and reimbursement than more speculative human-computer augmentation.
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
Which big generalist VCs have built real neurotech exposure?
GV and General Catalyst have the strongest repeat neurotech records among large generalist venture firms, while Lightspeed is becoming much more relevant now.
GV backed Neuralink years before its latest financing and has also invested in Cala Health and Beacon Biosignals. Those companies span implanted BCI, wearable neuromodulation and scalable EEG. The portfolio is small compared with Dolby's but clearly extends beyond one famous bet.
General Catalyst led Kernel's $53 million outside financing and became an early investor in Beacon Biosignals. Beacon is particularly useful evidence because General Catalyst stayed involved as the company grew from an early neural-data startup into a business that has now raised more than $130 million in total.
Lightspeed has moved up the list quickly. It participated in Neuralink's most recent giant financing and also returned in Science Corporation's $230 million round. Science described Lightspeed, Khosla, Y Combinator, IQT and Quiet Capital as existing investors rather than newcomers joining after the company's recent clinical results.
B Capital deserves a mention too. It invested in Precision Neuroscience at Series A and continued through the company's much larger Series C. That is exactly the follow-on pattern we look for in neurotech, even though B Capital does not have the sector breadth of GV.
| Investor | Neurotech companies that stand out | Our read |
|---|---|---|
| GV | Neuralink, Cala Health, Beacon Biosignals | Strong repeat exposure across several modalities |
| General Catalyst | Kernel, Beacon Biosignals | Particularly credible in neural measurement and data |
| Lightspeed | Neuralink, Science Corporation | Rapidly becoming a major late-stage neurotech investor |
| B Capital | Precision Neuroscience | Deep, repeated exposure to one serious BCI platform |
If you want more recent data on this point, please see our latest neurotechnology market report.
Are the famous Neuralink investors automatically top neurotech investors?
No. A place on Neuralink's cap table tells us that an investor wants Neuralink exposure, while a strong neurotech record requires more evidence.
Neuralink's large financing brought together ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, Qatar Investment Authority, Sequoia, Thrive, Valor Equity Partners and Vy Capital, among others. That is an exceptional group of investors, but their neurotech histories vary enormously.
Founders Fund had already led the previous Neuralink round, so we give that investment much more weight. GV backed Neuralink earlier and also has Cala and Beacon. Lightspeed now has Science as another serious neural-interface position.
For Sequoia, Thrive, ARK or QIA, Neuralink may still be one of very few visible neurotech positions. These investors can obviously become important sources of capital once a company reaches enormous scale. Their presence says less about who is actively searching for a pre-seed neural sensing company or who has spent years building pattern recognition around FDA-regulated implants.
Tether provides an even more extreme example. Its roughly $200 million investment for a majority position in Blackrock Neurotech instantly made it one of the biggest financial actors in BCI. We would still not put Tether ahead of re.Mind, Dolby or Khosla as a neurotech investor because we have not seen the same repeat investing record.
For founders, that distinction is practical. The investor with the biggest check in the sector is often different from the investor most likely to understand a new neurotech company before everyone else does.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Who should an early-stage neurotech founder actually approach first?
An early-stage neurotech founder should currently start with Dolby Family Ventures, re.Mind Capital, Satori Neuro and the specialist investors that already understand the exact technical route being attempted.
Dolby explicitly says it prioritizes first investments at pre-seed, seed and Series A. Its current portfolio shows that this is more than positioning. Paradromics, Motif and NeuroBionics all received Dolby backing while their technologies were still relatively early.
re.Mind is particularly attractive for BCI and neurological technology because a founder does not have to spend the first half of a pitch explaining why neural interfaces deserve a venture category. Its history with Blackrock Neurotech and Precision shows comfort with both long-established and newer implant architectures.
Satori becomes more interesting when the product mixes neurotechnology with mental health, sensing or therapeutic intervention. Its investment team brings unusually direct neuroscience and government R&D experience, and its portfolio has increasingly reflected that.
Prime Movers remains relevant when the technology is extremely ambitious and engineering-heavy. Its willingness to lead Paradromics twice, including at seed, is stronger evidence than a long portfolio of small passive checks would be.
Once the company has meaningful human data, the list changes. Khosla can become especially valuable because it can keep funding the company. ARCH has shown that it can step into clinical-stage BCI. Traditional medtech investors such as Arboretum, INKEF and Panakès become more relevant when reimbursement, clinical development and device commercialization start dominating the work.
The best neurotech syndicates often evolve this way. The investor that helps finance the first implant does not have to be the same investor that finances a pivotal trial or international launch.
Is the smart neurotech money moving beyond invasive brain implants?
Yes. Some of the most interesting neurotech investing today is moving toward less invasive stimulation, scalable neural sensing and devices with much clearer therapeutic use cases.
Beacon Biosignals is one of the best examples. Its latest financing took the Series B to $97 million and brought total funding above $130 million. Investors including GV, General Catalyst, Innoviva, S32, Catalio and Samsung Next are effectively betting that EEG can become scalable infrastructure for diagnostics, clinical trials and precision medicine.
NextSense is approaching neural measurement through earbuds with embedded EEG sensors. NeuroBionics is developing devices delivered through blood vessels rather than open brain surgery. Motif's DOT stimulator sits above the dura. Salvia's migraine system targets nerves using an ultra-thin implant.
These approaches can give up some of the bandwidth promised by intracortical systems while potentially making implantation, patient recruitment and commercialization much easier. For many medical applications, maximum neural bandwidth is not the only thing that determines whether a product works as a business.
The investor portfolios reflect that shift already. Dolby has exposure across almost the entire invasiveness spectrum. Satori spans implants and wearable sensing. GV combines Neuralink with Cala and Beacon. Khosla combines Synchron with Flow and Kernel.
We therefore expect the eventual neurotech winners to be spread across several architectures. The investment market is already behaving that way.
This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market
So who are the top investors in neurotech today?
Khosla Ventures is our top all-around neurotech investor today, while Dolby Family Ventures is the strongest dedicated specialist.
Khosla wins the overall ranking because we found repeat exposure across Synchron, Science Corporation, Kernel, Flow Neuroscience and Bionaut Labs, plus enough fund scale to keep backing companies after the capital requirements move from tens of millions into hundreds of millions.
Dolby comes extremely close and would be our first choice if specialization alone decided the ranking. Its active portfolio covers Paradromics, NeuroBionics, Motif, Cala, Salvia and several other neuroscience technologies, with fresh clinical and financing progress across multiple companies.
re.Mind ranks next because Blackrock Neurotech, Precision Neuroscience and Synchron give it one of the most concentrated serious BCI portfolios. Satori follows with a particularly strong position around therapeutic neurotech, sensing and brain health. Prime Movers earns a high place through very early, repeated conviction in Paradromics.
Founders Fund ranks highly because of its exceptional Neuralink commitment, though the portfolio remains concentrated. GV gets credit for real modality breadth. General Catalyst has a strong neural-measurement record. ARCH deserves a place because of the role it played taking Synchron deeper into clinical development. Lightspeed has climbed rapidly through Neuralink and Science and is probably the large generalist most likely to move further up this ranking if it keeps making neurotech bets.
The recent giant rounds can make the sector look dominated by a handful of famous late-stage names. The deeper portfolio history gives a different answer. The investors we would watch most closely are the ones that repeatedly showed up before neurotech became an obvious place to deploy large amounts of money.
| Rank | Investor | Why we rank it here |
|---|---|---|
| 1 | Khosla Ventures | Best mix of breadth, early conviction and follow-on firepower |
| 2 | Dolby Family Ventures | Deepest specialist portfolio across BCI, sensing and neuromodulation |
| 3 | re.Mind Capital | Exceptional concentration in serious BCI companies |
| 4 | Satori Neuro | Strong specialist in therapeutic neurotech, sensing and brain health |
| 5 | Prime Movers Lab | High-conviction early backing of frontier BCI |
| 6 | Founders Fund | One of the deepest and longest-running Neuralink bets |
| 7 | GV | Credible exposure across BCI, neuromodulation and EEG |
| 8 | General Catalyst | Strong record in neural measurement and brain-data platforms |
| 9 | ARCH Venture Partners | Important clinical-stage BCI investor through Synchron |
| 10 | Lightspeed Venture Partners | Growing quickly through major Neuralink and Science positions |
If you want more recent data on this point, please see our latest neurotechnology market report.
OUR METHODOLOGY
There is no single metric that identifies the top neurotech investor, so we separated the ranking into portfolio depth, breadth across neurotech modalities, timing of entry, repeated investment, follow-on behavior, company progress and the investor's ability to remain relevant as capital requirements increase.
We use a relatively narrow definition of neurotech. The core sample includes technologies that record from, stimulate or directly interface with the nervous system, including brain-computer interfaces, neuromodulation, neuroprosthetics and neural sensing. Conventional CNS drug developers are excluded unless the company's core technology directly interacts with neural activity.
We gave more weight to early investments followed by continued participation through technical, clinical, regulatory and financing milestones than to one-off appearances in large late-stage syndicates. We also gave more credit to portfolios that span genuinely different neural architectures rather than several bets on essentially the same approach.
The analysis prioritized recent, observable evidence: new financings, investor participation across successive rounds, human-trial progress, FDA milestones, commercialization plans and current portfolio activity. That makes the ranking a view of who is showing repeat conviction in neurotech now, not simply who has the longest historical neuroscience portfolio.
Key first-hand sources include Neuralink's $650 million Series E announcement, Synchron's company news and financing updates, Science Corporation's $230 million Series C announcement, Beacon Biosignals' expanded $97 million Series B, Paradromics' $20 million seed financing, Paradromics' $33 million Series A, re.Mind Capital's portfolio stories, GV's life-sciences portfolio, General Catalyst's investment note on Kernel, and ARCH Venture Partners' portfolio.
We aggregated those dimensions rather than letting deal count, check size or one famous company determine the result. The final ranking is therefore our assessment of the strongest combination of repeated conviction, portfolio quality, technical breadth, stage coverage and recent evidence of continued involvement in neurotech.
This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time
Related blog posts
- Where is there still room in neurotech?
